_What are the differences between the four domestically produced COVID-19 vaccines?
●Sinopharm
Beijing Biovaccine is the first domestically produced inactivated coronavirus vaccine to be approved. The vaccine can produce antibodies 10 days after the first shot and two to four weeks after vaccination. After the second injection, 14 days after the two injections, high-titer antibodies can be produced, forming effective protection. According to Sinopharm, the three-week and four-week intervals have the best effect, and various indicators such as the durability of immunity, the level of antibody seroconversion, and the average antibody value are better than the one-week and two-week intervals.
Sinopharm Group’s Wuhan Biotech vaccine was approved on February 25. Two Sinopharm vaccines have been approved for marketing in China. The first batch of the new inactivated vaccine developed by Sinopharm Wuhan Biotech was rolled out on February 28, with an annual output of up to 100 million doses. According to Sinopharm, Sinopharm’s inactivated COVID-19 vaccine has been approved and officially registered for marketing in the United Arab Emirates, Bahrain, Bolivia, and Seychelles. So far, more than 44 million doses have been administered at home and abroad.
●Beijing Sinovac Zhongwei Biotechnology Co., Ltd.’s new coronavirus inactivated vaccine
The vaccine received conditional approval for marketing on February 5. The first batch of 1 million doses of the Sinovac vaccine supplied to Hong Kong began to be available for public vaccination on February 26. Since January 2021, Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, Laos, Mexico, Thailand, Malaysia and other countries have been approved for emergency use of the Sinovac vaccine.
●CanSino Biologics' recombinant new coronavirus vaccine
This vaccine is one of the latest vaccines approved on February 25. It is currently the only new coronavirus vaccine in China that adopts a single-shot immunization procedure. vaccine. CanSino Biologics stated in the announcement that the interim analysis data of the Phase III clinical trial of this vaccine showed that 28 days after a single injection of the vaccine, the overall protective efficacy of the vaccine against all symptoms was 65.28; 14 days after a single injection of the vaccine, the vaccine had an overall protective efficacy of 65.28 against all symptoms. The overall protective efficacy for all symptoms was 68.83. During the Spring Festival of 2021, the vaccine has received emergency use authorization from Pakistan and Mexico.
In addition to the above four self-developed COVID-19 vaccines, Fosun Pharma has been authorized by BioNTechSE to be the exclusive agent of the mRNA COVID-19 vaccine in mainland China, Hong Kong, Macao and Taiwan. On the morning of February 27, the first batch of vaccines arrived at Hong Kong International Airport in China and will be supplied to Hong Kong and Macau respectively. Currently, they are not yet available in mainland China.
_How safe are the four domestic COVID-19 vaccines?
The protective efficacy data results published by the domestic COVID-19 vaccines currently approved for marketing with conditions meet the relevant technical standards of the World Health Organization and Relevant national technical standards. Academician Chen Wei said that as long as it is approved by the State Food and Drug Administration, its safety and effectiveness are supported by certain data, that is, the potential benefits, or the known benefits are definitely greater than the potential risks, or the known benefits of risk. "I think it's the same whether you make any choice about which vaccine to take. But if you want to take less frequent vaccinations, or if you want to take one shot and have to go abroad or perform a mission, we may be the first choice."